However, it should be noted that anti-tumor agents, especially naturally occurring compounds suffer from poor bioavailability [204,205], and using carriers such as nanostructures for their delivery can remarkably promote their potential in down-regulating Nrf2 signaling and enhancing DOX sensitivity of cancer cells. The gene discussed is NFE2L2; the disease is cancer.